Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ipilimumab biosimilar - Henlix Biotech

Next Previous
Drug Profile

Ipilimumab biosimilar - Henlix Biotech

Alternative Names: HLX-13

Latest Information Update: 29 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Henlix Biotech
  • Developer Shanghai Henlius Biotech
  • Class Antineoplastics; Antiretrovirals; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Colorectal cancer; Endometrial cancer; Liver cancer; Malignant melanoma; Malignant-mesothelioma; Non-small cell lung cancer; Renal cell carcinoma

Most Recent Events

  • 16 May 2025 Phase-I/III clinical trials in Liver cancer (Late-stage disease, Metastatic disease, First-line therapy, Inoperable/Unresectable, In combination therapy) in China (IV) (NCT06841185)
  • 29 Apr 2025 Sandoz in-licenses ipilimumab biosimilar from Shanghai Henlius Biotech for commercialization in USA, Japan, Australia, Europe and USA
  • 24 Feb 2025 Shanghai Henlius Biotech plans to initiate a phase III trial for Hepatocellular Carcinoma (First-line therapy, Unresectable diseases, Metastatic disease, In combination therapy, Late-stage disease) (Parenteral) (NCT06841185)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top